Speeding malaria vaccine development with humanized mouse models
Accelerating Malaria Vaccines with a Custom Preclinical Humanized Mouse Model Platform
This project uses specially engineered mice that carry human-like immune cells to help create better vaccines to protect people—especially children—against malaria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11310010 on NIH RePORTER |
What this research studies
If you or your child are at risk of malaria, this work uses mice engineered to carry human-like B cells so scientists can test which vaccine pieces make the strongest protective antibodies. The team focuses on parts of the malaria circumsporozoite protein (CSP) and a promising antibody called CIS43 to design vaccines that block infection early. Researchers give mice different small pieces of the protein and measure the antibody responses to find the most promising vaccine candidates. This is lab-based preclinical work intended to speed safer and more effective vaccines toward human testing.
Who could benefit from this research
Good fit: Ultimately, ideal candidates for vaccines developed from this work would be people living in malaria-endemic regions, including young children who bear the highest burden of disease.
Not a fit: People needing immediate malaria treatment, those who cannot mount normal antibody responses, or those not exposed to malaria are unlikely to receive direct benefit from this preclinical work.
Why it matters
Potential benefit: If successful, this could produce vaccine designs that prevent malaria infection more reliably and protect more people, especially children in high-risk areas.
How similar studies have performed: Related approaches have already produced a powerful antibody (CIS43) now in clinical trials, and this model has generated even more effective variants in animal tests, so it builds on promising preclinical results.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Batista, Facundo Damian — Massachusetts General Hospital
- Study coordinator: Batista, Facundo Damian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.